Reuters logo
BRIEF-Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia
November 13, 2017 / 12:45 PM / a month ago

BRIEF-Allergan receives FDA approval for use of Vraylar in maintenance treatment of schizophrenia

Nov 13 (Reuters) - Allergan Plc

* Allergan receives FDA approval for use of Vraylar (cariprazine) in the maintenance treatment of schizophrenia

* Allergan - ‍Vraylar is approved in U.S. in adults for acute treatment of schizophrenia & acute treatment of manic/ mixed episodes of bipolar I disorder​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below